Joseph Brueggen

1.1k total citations
11 papers, 895 citations indexed

About

Joseph Brueggen is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joseph Brueggen has authored 11 papers receiving a total of 895 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joseph Brueggen's work include Angiogenesis and VEGF in Cancer (3 papers), Chemical Synthesis and Analysis (2 papers) and Click Chemistry and Applications (2 papers). Joseph Brueggen is often cited by papers focused on Angiogenesis and VEGF in Cancer (3 papers), Chemical Synthesis and Analysis (2 papers) and Click Chemistry and Applications (2 papers). Joseph Brueggen collaborates with scholars based in Switzerland, Germany and Israel. Joseph Brueggen's co-authors include Peter R. Allegrini, Éric Biron, Oded Ovadia, Paul M.J. McSheehy, Horst Kessler, Raz Jelinek, Daniel Langenegger, Herbert Schmid, Chaim Gilon and Daniël Hoyer and has published in prestigious journals such as Angewandte Chemie International Edition, Cancer Research and Clinical Cancer Research.

In The Last Decade

Joseph Brueggen

11 papers receiving 883 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph Brueggen Switzerland 8 617 216 115 105 103 11 895
Junxian Lim Australia 21 543 0.9× 138 0.6× 25 0.2× 147 1.4× 70 0.7× 42 1.1k
Uma Yasothan United States 22 608 1.0× 433 2.0× 143 1.2× 236 2.2× 80 0.8× 30 1.4k
Wengen Wu United States 14 480 0.8× 353 1.6× 27 0.2× 172 1.6× 127 1.2× 23 821
Qiaodan Zhou China 10 535 0.9× 132 0.6× 45 0.4× 72 0.7× 27 0.3× 21 815
Elizabeth McAvoy United States 14 710 1.2× 349 1.6× 68 0.6× 111 1.1× 29 0.3× 23 1.1k
Elena Bevilacqua United States 18 617 1.0× 157 0.7× 48 0.4× 44 0.4× 35 0.3× 24 1.0k
Percy H. Carter United States 23 680 1.1× 444 2.1× 28 0.2× 630 6.0× 90 0.9× 59 1.5k
Laurie Churchill United States 13 686 1.1× 263 1.2× 124 1.1× 260 2.5× 146 1.4× 20 1.3k
Wen‐Cherng Lee United States 15 627 1.0× 224 1.0× 58 0.5× 132 1.3× 28 0.3× 21 1000

Countries citing papers authored by Joseph Brueggen

Since Specialization
Citations

This map shows the geographic impact of Joseph Brueggen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Brueggen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Brueggen more than expected).

Fields of papers citing papers by Joseph Brueggen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Brueggen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Brueggen. The network helps show where Joseph Brueggen may publish in the future.

Co-authorship network of co-authors of Joseph Brueggen

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Brueggen. A scholar is included among the top collaborators of Joseph Brueggen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Brueggen. Joseph Brueggen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Shi, Michael, Ronald Linnartz, Richard Versace, et al.. (2011). Abstract 3575: Dovitinib (TKI258), a dual inhibitor of FGFR and VEGFR, induces tumor growth suppression in xenograft models of human bladder cancer. Cancer Research. 71(8_Supplement). 3575–3575. 2 indexed citations
2.
Wöhrle, Simon, Olivier Bonny, Swann Gaulis, et al.. (2011). FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. Journal of Bone and Mineral Research. 26(10). 2486–2497. 120 indexed citations
3.
Martiny‐Baron, Georg, Philipp Holzer, Éric Billy, et al.. (2010). The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 13(3). 259–267. 105 indexed citations
4.
Lane, Heidi A., Jeanette M. Wood, Paul M.J. McSheehy, et al.. (2009). mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor. Clinical Cancer Research. 15(5). 1612–1622. 196 indexed citations
5.
O’Reilly, Terence, Paul M.J. McSheehy, R. Kawai, et al.. (2009). Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemotherapy and Pharmacology. 65(4). 625–639. 55 indexed citations
6.
Biron, Éric, Jayanta Chatterjee, Oded Ovadia, et al.. (2008). Improving Oral Bioavailability of Peptides by Multiple N‐Methylation: Somatostatin Analogues. Angewandte Chemie International Edition. 47(14). 2595–2599. 304 indexed citations
7.
Biron, Éric, Jayanta Chatterjee, Oded Ovadia, et al.. (2008). Die Verbesserung der oralen Bioverfügbarkeit von Peptiden durch multiple N‐Methylierung: Somatostatin‐Analoga. Angewandte Chemie. 120(14). 2633–2637. 40 indexed citations
8.
O’Reilly, Terence, Markus Wartmann, Joseph Brueggen, et al.. (2008). Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemotherapy and Pharmacology. 62(6). 1045–1054. 60 indexed citations
9.
10.
11.
Friedlos, Frank, Stephen M. Stribbling, Jean‐Christian Roussel, et al.. (2003). A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. British Journal of Cancer. 88(10). 1622–1630. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junxian Lim Breakdown of academic impact, for papers by Uma Yasothan Breakdown of academic impact, for papers by Wengen Wu Breakdown of academic impact, for papers by Qiaodan Zhou Breakdown of academic impact, for papers by Elizabeth McAvoy Breakdown of academic impact, for papers by Elena Bevilacqua Breakdown of academic impact, for papers by Percy H. Carter Breakdown of academic impact, for papers by Laurie Churchill Breakdown of academic impact, for papers by Wen‐Cherng Lee
Rankless by CCL
2026